MANCHESTER, England — Febuxostat (Uloric) did not appear to increase the risk for major adverse cardiovascular (CV) events (MACEs) when compared with no urate-lowering therapy (ULT) in people with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback